Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, April 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0842985/Myelofibrosis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Myelofibrosis Therapeutics market. The report identifies the key trends shaping and driving the global Myelofibrosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myelofibrosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Myelofibrosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myelofibrosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Myelofibrosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myelofibrosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myelofibrosis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Myelofibrosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myelofibrosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Myelofibrosis Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Myelofibrosis Therapeutics - Introduction 6
2.1 Overview 6
2.2 Classification of Myelofibrosis 6
2.2.1 Primary Myelofibrosis 6
2.2.2 Secondary Myelofibrosis 6
2.3 Epidemiology 7
2.4 Etiology and Pathophysiology 7
2.4.1 Abnormalities of the Hematopoietic Stem Cells 8
2.4.2 Gene Mutation in JAK2 Enzyme 8
2.5 Risk Factors 9
2.6 Symptoms 9
2.7 Diagnosis of Myelofibrosis 10
2.7.1 Physical Examination 10
2.7.2 Full Blood Count 10
2.7.3 Bone Marrow Examination 10
2.7.4 Gene Test 10
2.8 Referral Pathway 11
2.9 Treatment 11
2.9.1 Allogeneic Stem Cell Transplantation 13
2.9.2 Treatment for Anemia 13
2.9.3 Treatment for Enlarged Spleen 14
2.9.4 Interferon Alpha 14
2.9.5 Cytotoxic Agents 14
2.9.6 Anagrelide 14
2.9.7 JAK2 Inhibitors 14
2.10 GlobalData Pipeline Report Guidance 15
3 Myelofibrosis Therapeutics - Market Characterization 16
3.1 Major Markets, Market Size (2006-2011) 16
3.2 Major Markets, Market Forecast (2011-2019) 18
3.3 Myelofibrosis Therapeutics Market Size (2006-2011) - The US 20
3.4 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The US 21
3.5 Myelofibrosis Therapeutics Market Size (2006-2011) - The UK 22
3.6 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The UK 23
3.7 Myelofibrosis Therapeutics Market Size (2006-2011) - France 24
3.8 Myelofibrosis Therapeutics Market Forecast (2011-2019) - France 25
3.9 Myelofibrosis Therapeutics Market Size (2006-2011) - Germany 26
3.10 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Germany 27
3.11 Myelofibrosis Therapeutics Market Size (2006-2011) - Italy 28
3.12 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Italy 29
3.13 Myelofibrosis Therapeutics Market Size (2006-2011) - Spain 30
3.14 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Spain 31
3.15 Myelofibrosis Therapeutics Market Size (2006-2011) - Japan 32
3.16 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Japan 33
3.17 Drivers and Barriers for the Myelofibrosis Therapeutics Market 34
3.17.1 Drivers of the Myelofibrosis Therapeutics Market 34
3.17.2 Barrier to the Myelofibrosis Therapeutics Market 34
3.18 Key Events Impacting the Future Market 35
3.19 Opportunity and Unmet Need 36
3.20 Key Takeaway 36
4 Myelofibrosis Therapeutics Market - Competitive Assessment 37
4.1 Overview 37
4.1.1 Strategic Competitor Assessment 37
4.2 Profiles of Commonly Used Products in the Myelofibrosis Therapeutics Market 37
4.2.1 5.2.1 Jakafi (ruxolitinib) 37
4.3 Key Takeaway 38
5 Myelofibrosis Therapeutics Market - Pipeline Assessment 39
5.1 Overview 39
5.2 Strategic Pipeline Assessment 39
5.2.1 Myelofibrosis Therapeutics - Phase III Pipeline 40
5.2.2 Myelofibrosis Therapeutics - Phase II Pipeline 40
5.2.3 Myelofibrosis Therapeutics - Phase I/II Pipeline 40
5.2.4 Myelofibrosis Therapeutics - Phase I Pipeline 41
5.3 Myelofibrosis Therapeutics Pipeline by Mechanism of Action 41
5.4 Myelofibrosis Therapeutics Technology Trends Analytical Framework 42
5.5 Myelofibrosis Therapeutics - Promising Drugs under Clinical Development 43
5.6 Molecule Profile for Late-stage under Clinical Development 44
5.6.1 Actimid (pomalidomide) 44
5.6.2 SAR302503 (TG 101348) 45
5.7 Key Takeaway 45
6 Myelofibrosis Therapeutics - Clinical Trials Mapping 46
6.1 Clinical Trials by Country (US, EU5 and Japan) 46
6.2 Clinical Trials by Phase 47
6.3 Clinical Trials by Trial Status 48
6.4 Overall Sponsors 49
6.5 Prominent Sponsors 50
6.6 Top Companies Participating in Myelofibrosis Clinical Trials 51
7 Myelofibrosis Therapeutics - Strategic Assessment 52
7.1 Myelofibrosis Therapeutics - Implications for Future Market Competition 52
8 Myelofibrosis Therapeutics - Future Players in the Market 53
8.1 Introduction 53
8.1.1 Sanofi 53
8.1.2 Celgene 55
8.1.3 Gilead Sciences 57
8.1.4 YM BioSciences Inc. 59
8.1.5 Novartis AG 59
8.1.6 S*BIO 61
8.1.7 Other Companies in Myelofibrosis Therapeutics Market 62
9 Myelofibrosis - Licensing and Partnership Deals 63
10 Myelofibrosis Therapeutics - Appendix 65
10.1 Definitions 65
10.2 Acronyms 65
10.3 Research Methodology 66
10.3.1 Coverage 66
10.3.2 Secondary Research 66
10.3.3 Forecasting 67
10.3.4 Primary Research 68
10.3.5 Expert Panel Validation 68
10.4 Contact Us 69
10.5 Disclaimer 69
10.6 Bibliography 69
List of Tables
Table 1: Myelofibrosis- Prevalence, Major Markets, 2011 7
Table 2: Causes of Myelofibrosis 7
Table 3: Classification of Myelofibrosis Patients 11
Table 4: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011 16
Table 5: Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 18
Table 6: Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Table 7: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Table 8: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 22
Table 9: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 23
Table 10: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011 24
Table 11: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019 25
Table 12: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 26
Table 13: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 27
Table 14: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 28
Table 15: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 29
Table 16: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 30
Table 17: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 31
Table 18: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Table 19: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Table 20: Myelofibrosis Therapeutics - Phase III Pipeline 40
Table 21: Myelofibrosis Therapeutics - Phase II Pipeline 40
Table 22: Myelofibrosis Therapeutics - Phase I/II Pipeline 40
Table 23: Myelofibrosis Therapeutics - Phase I Pipeline 41
Table 24: Myelofibrosis Therapeutics - Promising Drugs under Clinical Development, 2011 43
Table 25: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011 46
Table 26: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011 47
Table 27: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011 48
Table 28: Myelofibrosis Therapeutics-Overall Sponsors, 2011 49
Table 29: Myelofibrosis Therapeutics - Prominent Sponsors, 2011 50
Table 30: Myelofibrosis Therapeutics - Top Companies Participating in Clinical Trials, 2011 51
Table 31: Sanofi - Myelofibrosis Therapeutics Pipeline 55
Table 32: Cephalon, Inc. - Myelofibrosis Therapeutics Pipeline 57
Table 33:Gilead Sciences Inc. - Myelofibrosis Therapeutics Pipeline 58
Table 34: YM BioSciences Inc. - Myelofibrosis Therapeutics Pipeline 59
Table 35: Novartis AG - Myelofibrosis Therapeutics Pipeline 61
Table 36: S*BIO- Myelofibrosis Therapeutics Pipeline 61
Table 37: Myelofibrosis Therapeutics Market- Future Players 62
Table 38: Myelofibrosis: Licensing and Partnership Deals 63
List of Figures
Figure 1:Role of JAK Pathway in Myelofibrosis 8
Figure 2: Risk Factors for Myelofibrosis 9
Figure 3: Bone Marrow Biopsy in Myelofibrosis 10
Figure 4: Referral Pathway 11
Figure 5: Treatment for Low Risk and High Risk Patients of Myelofibrosis 12
Figure 6: Treatment for Intermediate Risk Patients of Myelofibrosis 13
Figure 7: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011 16
Figure 8:Myelofibrosis Therapeutics Market Share ($m), 2011 17
Figure 9:Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019 18
Figure 10: Myelofibrosis, Market Share ($m), 2019 19
Figure 11:Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Figure 12: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019 21
Figure 13: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 22
Figure 14: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019 23
Figure 15: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011 24
Figure 16: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019 25
Figure 17: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 26
Figure 18: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019 27
Figure 19: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 28
Figure 20: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019 29
Figure 21: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 30
Figure 22: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019 31
Figure 23: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 32
Figure 24: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019 33
Figure 25: Myelofibrosis Therapeutics Market, Drivers and Restraints 2011 35
Figure 26: Opportunity and Unmet Need in the Myelofibrosis Therapeutics Market, 2011 36
Figure 27: Myelofibrosis Therapeutics - Pipeline by Phase of Clinical Development, 2011 39
Figure 28: Myelofibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 41
Figure 29: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline, 2011 42
Figure 30: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline - Description, 2011 43
Figure 31: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011 46
Figure 32: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011 47
Figure 33: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011 48
Figure 34: Myelofibrosis Therapeutics - Overall Sponsors, 2011 49
Figure 35: Myelofibrosis Therapeutics - Prominent Sponsors, 2011 50
Figure 36: Myelofibrosis Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 51
Figure 37: Implications for Future Market Competition in the Myelofibrosis Therapeutics Market, 2011 52
Figure 38: Myelofibrosis Therapeutics Market - Clinical Pipeline by Company, 2011 53
Companies mentioned
Sanofi
Celgene
Gilead Sciences
YM BioSciences Inc.
Novartis AG
S*BIO
To order this report:
Therapy Industry: Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article